Synergistic interactions between CK2 and MYC might lead to lymphocytes’ transformation; indeed, CK2 inhibitors, acting as an IKZF1 activator, suppress c-MYC in an Ikaros-dependent manner in ALL cells [14]. The gene discussed is MYC; the disease is acute lymphoblastic leukemia.